LIVR News

Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases including NASH, withdrew its plans for an initial public offering on Tuesday. It originally filed in April 2014 with a proposed deal size of $75 million. In May 2014, it agreed to be bought by the Irish pharmaceutical company Shire (NASDAQ: SHPG) for $260 million plus milestone...read more

Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The San Diego, CA-based company, which was founded in 2011, plans to list on the NASDAQ under the symbol LIVR. Lumena Pharmaceuticals initially filed confidentially on February 28, 2014. Citi,...read more